OMVOH

This brand name is authorized in United States. It is also authorized in Austria, Croatia, France, Ireland, Italy, Japan, Lithuania.

Active ingredients

The drug OMVOH contains one active pharmaceutical ingredient (API):

1	Mirikizumab UNII Z7HVY03PHP - MIRIKIZUMAB
	Mirikizumab is a humanised IgG4 monoclonal, anti-interleukin-23 (anti-IL-23) antibody that selectively binds to the p19 subunit of human IL-23 cytokine and inhibits its interaction with the IL-23 receptor. In humans, selective blockade of IL-23 was shown to normalise production of effector cytokines, including IL-17A, IL-17F and IL-22 that drive inflammatory disease.
	Read more about Mirikizumab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
OMVOH Concentrate for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L04AC24		L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AC Interleukin inhibitors
Discover more medicines within L04AC24

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
FR	Base de données publique des médicaments	62045244, 62404327, 68364081
IT	Agenzia del Farmaco	050695016, 050695028, 050695030, 050695042, 050695055, 050695067
JP	医薬品医療機器総合機構	23994A5A1026, 23994A5G1029, 23994A5G2025
LT	Valstybinė vaistų kontrolės tarnyba	1097213, 1097214, 1097215, 1097216, 1097217, 1097218
US	FDA, National Drug Code	0002-7575, 0002-8011, 0002-8870